U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07064681) titled 'The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)' on July 05.
Brief Summary: This is an observational study. All patients who meet the inclusion criteria of our previous Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable hepatocellular carcinoma, but refuse to receive neoadjuvant treatment will be asked again to participate this observational study retrospectively and prospectively. Participants will receive surgery and regular monitoring for 1 year. The purpose is to provide real-world cohort for compar...